ClinicalTrials.gg
CompletedNCT03444714Updated Sep 15, 2025

Phase I Study of RiMO-301 With Radiation in Advanced Tumors

A Phase 1 interventional study of RiMO-301 in Advanced Tumors, sponsored by Coordination Pharmaceuticals, Inc.. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-15.

Sponsored by Coordination Pharmaceuticals, Inc. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Jun 2025, 1 year 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a prospective, open-label, single arm, non-randomized study of RiMO-301 with radiation in patients with advanced tumors. A single escalation dose of RiMO-301 is intratumorally injected in a 3 + 3 study design to identify the recommended dose and dosing volumes.

Condition or Disease:

Patient with advanced tumor which is clinically accessible for intratumoral injection

Intervention/Treatment:

Drug - RiMO-301

Radiation - Radiotherapy

Phase:

Phase 1

Read the detailed description

Primary Objectives:

  • The primary objective is to determine the maximum tolerated dose (MTD) of RiMO-301 as determined by toxicity observed in patients treated with palliative radiation doses

Secondary Objectives:

  • To determine clinical response after RiMO-301 and radiotherapy as assessed by clinical response rate using clinical evaluation, imaging and/or symptom relief
  • To characterize adverse events of RiMO-301 in patients with advanced cancers
  • To evaluate the pharmacokinetics (PK) of RiMO-301 with radiation

The target population is patients with clinically accessible lesions for intratumoral injection. Up to 3 dose levels (5%, 10%, and 15% of the total baseline tumor volume, respectively) will be tested in a 3 + 3 dose escalation study design. MTD will be defined as the dose associated with a dose limiting toxicity (DLT) in less than or equal to 33% of patients at the dose level tested. Dose limiting toxicity (DLT) is defined as one of the following events occurring from the intratumor injection of RiMO-301 to 30 days after the completion of radiation treatment:

  • Grade 4 or greater treatment related hematologic or dermatologic toxicity
  • Any Grade 3 or greater treatment related non-hematologic, non-dermatologic toxicity (excluding nausea, vomiting or diarrhea without maximal medical intervention)
02

Conditions studied

  • Advanced Tumors

Keywords

  • intratumoral
03

In context

Lead sponsor

Coordination Pharmaceuticals, Inc. is the lead sponsor of 6 studies on the registry; 1 is open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of advanced or cancer not amenable to curative therapy
  • Lesion that is amenable to palliative radiotherapy
  • Lesion that is technically feasible to irradiation and accessible for direct intratumoral injection
  • Target tumor in region not in previously irradiated field
  • Patient must have recovered from acute toxic effects (≤ grade 1) of previous cancer treatments prior to enrollment
  • Age >18 years
  • Has , defined as at least 1 tumor that fulfills the criteria for a target lesion
  • Females with child bearing age should be using adequate measures, should not be breast feeding and must have a negative pregnancy test prior to the start of dosing
  • Patients must sign a study-specific form prior to study entry

Exclusion criteria

Exclusion Criteria:

  • Patients with a histological diagnosis of lymphomas and/or leukemias
  • Patients may not have received chemotherapy, targeted therapies, biologic response modifiers and/or hormonal therapy within the last 14 days
  • Ongoing infection at or near the incident lesion
  • Major surgery over the target area (excluding placement of vascular access) \<21 days from beginning of the study drug or minor surgical procedures \<7 days
  • Other severe acute or chronic medical or psychiatric conditions or laboratory abnormality that would make the patient inappropriate for enrollment in this study
  • Has any mental or medical condition that prevents the patient from giving or participating in the trial
  • Pregnant and nursing women
  • Patients with a target lesion located in a previously irradiated field
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    RiMO-301+Radiotherapy

    3 dose levels (5%, 10%, and 15% of the total baseline tumor volume, respectively) will be tested in a 3 + 3 dose escalation study

    Drug: RiMO-301

Interventions

  • DrugMOF Compound RiMO-301Studies of MOF Compound RiMO-301MOF Compound RiMO-301 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Drug: RiMO-301 RiMO-301 will be administered by intratumoral route as slow injection Radiotherapy Patients will receive 10 fractions of 3 Gy each over 2 weeks

    Also known as: Radiotherapy

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose (MTD)

    • To determine the maximum tolerated dose (MTD), which is defined as the dose level at which fewer than 33% of patients experience a dose limiting toxicity (DLT) using a 3+3 strategy

    Time frame: 45 days

Secondary outcomes

  1. clinical benefit

    • To assess clinical benefit by change in tumor size and resolution of symptoms, which will be reported as response rate (%)

    Time frame: 45 days

  2. adverse effect

    • To assess adverse effect as either treatment-related or non-treatment-related as defined by CTCAE

    Time frame: 45 days

  3. Maximum Plasma Concentration [Cmax]

    • To evaluate Maximum Plasma Concentration \[Cmax\] of RiMO-301 in patients tested

    Time frame: 45 days

  4. Area Under the Curve [AUC]

    To evaluate Area Under the Curve \[AUC\] of RiMO-301 in patients tested

    Time frame: 45 days

07

Study locations

2 sites
  • University of Illinois at Chicago
    Chicago, Illinois 60612, United States
  • University of Chicago Medical Center
    Chicago, Illinois 60637, United States
08

References and documents

Individual participant data

Plan to share: No — The data will not be shared due to confidentiality agreements

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2018 to primary completion in Jun 2025, 86 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2018
First posted
Feb 23, 2018
StartActual
Apr 10, 2018
Primary completionActual
Jun 16, 2025
CompletionActual
Jun 16, 2025
Last update
Sep 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03444714
Lead sponsor
Coordination Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Feb 23, 2018
Start date
Apr 10, 2018
Primary completion
Jun 16, 2025
Completion
Jun 16, 2025
Last update
Sep 15, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MOF Compound RiMO-301

Start the discussion